Methylamine

Methylamine

SCHEMBL1240924

CN.[CH2]C

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylene SCHEMBL2263980 0.80
Ethylene SCHEMBL10629484 0.80
Methylamine SCHEMBL1331361 0.78
Methylamine SCHEMBL1331336 0.78
SCHEMBL178 0.78
SCHEMBL1246904 0.78
Methylamine SCHEMBL1330940 0.78
Methylamine SCHEMBL6988408 0.78
Methylamine SCHEMBL31337913 0.78
Methylamine SCHEMBL632 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11547665-B2 Multiphasic compositions SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) 2023-01-10 US disclosed
EP-3954361-A1 MULTIPHASIC COMPOSITIONS Sequessome Technology Holdings Limited (MT) 2022-02-16 EP disclosed
US-20210393655-A1 Vesicular Formulations for Use in the Treatment of Pain or Reduced Mobility of a Joint SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) 2021-12-23 US disclosed
EP-3316857-B1 MULTIPHASIC COMPOSITIONS SEQUESSOME TECH HOLDINGS LIMITED (MT) 2021-08-04 EP disclosed
US-20210007989-A1 MULTIPHASIC COMPOSITIONS SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) 2021-01-14 US disclosed
US-10744090-B2 Multiphasic compositions SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) 2020-08-18 US disclosed
US-20180311148-A1 MULTIPHASIC COMPOSITIONS SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) 2018-11-01 US disclosed
EP-2437726-B1 FORMULATIONS FOR THE TREATMENT OF DEEP TISSUE PAIN SEQUESSOME TECH HOLDINGS LIMITED (MT) 2018-05-16 EP disclosed
EP-3316857-A1 MULTIPHASIC COMPOSITIONS Sequessome Technology Holdings Limited (MT) 2018-05-09 EP disclosed
US-20170128473-A1 Vesicular Formulations for Use in the Treatment of Pain or Reduced Mobility of a Joint SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) 2017-05-11 US disclosed
WO-2011022707-A1 VESICULAR FORMULATIONS KROON HENK-ANDRE (US) 2011-02-24 WO disclosed
WO-2010140061-A2 FORMULATIONS FOR THE TREATMENT OF DEEP TISSUE PAIN MAYO JOHN CHARLES (GB) 2010-12-09 WO disclosed
US-7820720-B2 Topical terbinafine formulations and methods of administering same for the treatment of fungal infections TDT LIMITED (MT) 2010-10-26 US disclosed
WO-2010090654-A1 METHODS OF REDUCING THE PROLIFERATION AND VIABILITY OF MICROBIAL AGENTS TDT, LTD. (MT) 2010-08-12 WO disclosed
US-20100197621-A1 METHODS OF REDUCING THE PROLIFERATION AND VIABILITY OF MICROBIAL AGENTS TARGETED DELIVERY TECHNOLOGIES LIMITED (MT) 2010-08-05 US disclosed
US-20100104633-A1 antifungal formulations comprising terbinafine or a pharmaceutically acceptable salt thereof, a lipid, and a surfactant; uses thereof for the treatment of skin and nail fungal infections CEVC GREGOR 2010-04-29 US disclosed
US-20100086504-A1 METHODS OF ADMINISTERING TOPICAL ANTIFUNGAL FORMULATIONS FOR THE TREATMENT OF FUNGAL INFECTIONS TDT LIMITED (MT) 2010-04-08 US disclosed
WO-2010010470-A2 METHODS OF ADMINISTERING TOPICAL ANTIFUNGAL FORMULATIONS FOR THE TREATMENT OF FUNGAL INFECTIONS TDT, LTD (MT) 2010-01-28 WO disclosed
CN-101506242-A 1, 2-dithiol-3-thiones as chain transfer agents in free-radical polymerization BASF SE (DE) 2009-08-12 CN disclosed
US-20020048596-A1 PREPARATION FOR THE TRANSPORT OF AN ACTIVE SUBSTANCE ACROSS BARRIERS IDEA AG (DE) 2002-04-25 US disclosed